美国ALCHEMIST研究(Alliance A151216)中早期肺癌患者接受指南一致性手术与辅助化疗的比例
该回顾性队列研究纳入2014年8月18日至2019年4月1日ALCHEMIST筛查研究(A151216)中2833例IB-IIIA期NSCLC患者,评估指南一致性治疗模式。结果显示95%接受解剖性切除,仅53%行充分淋巴结清扫,57%接受辅助化疗,34%接受含顺铂方案。作者认为这些结果可能影响辅助治疗试验的解读。
要点
- 2833例IB-IIIA期NSCLC患者中,95%接受解剖性手术切除。
- 仅53%接受充分淋巴结清扫(≥1个N1站+≥3个N2站)。
- 57%接受任何辅助化疗,34%接受含顺铂辅助化疗。
核心结论
- 在辅助治疗临床试验筛查方案入组的切除早期NSCLC患者中,仅53%接受充分淋巴结清扫,57%接受辅助化疗,尽管存在相应治疗指征。
- 这些结果可能影响辅助治疗试验的解读。
- 需要努力优化早期NSCLC中已证实疗法的使用。
研究设计与样本
- 回顾性队列研究,纳入2014年8月18日至2019年4月1日ALCHEMIST筛查研究(Alliance A151216)中2833例IB-IIIA期NSCLC患者(按AJCC第7版标准),且未入组治疗性辅助临床试验;患者肿瘤至少4cm和/或淋巴结阳性。
- 统计分析于2020年6月1日至2021年10月1日进行。
主要发现
- 2833例患者中,1505例为女性(53%),平均(SD)年龄66.5(9.2)岁。
- 2697例(95%)接受解剖性手术切除。
- 1513例(53%)接受充分淋巴结清扫(≥1个N1站+≥3个N2站)。
- 1617例(57%)接受任何辅助化疗;1237例(44%)接受至少4周期辅助含铂化疗;965例(34%)接受任何含顺铂辅助化疗。
- 各种族和民族间比例相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard treatment for resectable non-small cell lung cancer (NSCLC) includes anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for appropriate patients. Historically, many patients with early-stage NSCLC have not received such treatment, which may affect the interpretation of the results of adjuvant therapy trials. OBJECTIVE: To ascertain patterns of guideline-concordant treatment among patients enrolled in a US-wide screening protocol for adjuvant treatment trials for resected NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 2833 patients with stage IB to IIIA NSCLC (per American Joint Committee on Cancer 7th edition criteria) who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study (Alliance for Clinical Trials in Oncology A151216) from August 18, 2014, to April 1, 2019, and who did not enroll in a therapeutic adjuvant clinical trial; patients had tumors of at least 4 cm and/or with positive lymph nodes. Statistical analysis was conducted from June 1, 2020, through October 1, 2021. EXPOSURES: Care patterns were ascertained overall and by sociodemographic and clinical factors, including age, sex, race and ethnicity, educational level, marital status, geography, histologic characteristics, stage, genomic variant status, smoking history, and comorbidities. MAIN OUTCOMES AND MEASURES: Five outcomes are reported: whether patients (1) had anatomic surgical resection, (2) had adequate lymph node dissection (≥1 N1 nodal station plus ≥3 N2 nodal stations), (3) received any adjuvant chemotherapy, (4) received any cisplatin-based adjuvant chemotherapy, and (5) received at least 4 cycles of adjuvant chemotherapy. RESULTS: Of the 2833 patients (1505 women [53%]; mean [SD] age, 66.5 [9.2] years) included in this analysis, 2697 (95%) had anatomic surgical resection, 1513 (53%) had adequate lymph node dissection, 1617 (57%) received any adjuvant chemotherapy, 1237 (44%) received at least 4 cycles of adjuvant platinum-based chemotherapy, and 965 (34%) received any cisplatin-based adjuvant chemotherapy. Rates were similar across race and ethnicity. CONCLUSIONS AND RELEVANCE: This cohort study found that among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, just 53% underwent adequate lymph node dissection, and 57% received adjuvant chemotherapy, despite indications for such treatment. These results may affect the interpretation of adjuvant trials. Efforts are needed to optimize the use of proven therapies for early-stage NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02194738.
引用
- Kehl KL, Zahrieh D, Yang P, et al. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022. PMID: 35297944. doi:10.1001/jamaoncol.2022.0039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。